DERMIRA, INC.
INDIANAPOLIS, IN

We are looking deeper. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. We are focused on delivering important new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding and addressing the needs of both patients and physicians. We are using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. Dermira announces the Phase 3 program for olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in patients with acne vulgaris and expects to discontinue the program Dermira and UCB announce that the companies agreed to end a development and commercialization agreement for CIMZIA (certolizumab pegol) in psoriasis Dermira raises $278 million through a convertible debt financing Dermira raises $182 million through a follow-on equity financing Dermira announces positive results from CIMPACT, the final Phase 3 CIMZIA Dermira begins a Phase 3 program for olumacostat glasaretil (formerly DRM01) in patients with acne vulgaris Dermira reaches a market value of $1 billion+ Dermira begins a Phase 3 program for olumacostat glasaretil (formerly DRM01) in patients with acne vulgaris Dermira announces positive topline results from CIMPASI-1 and CIMPASI-2, the first two trials from the Phase 3 clinical program evaluating CIMZIA as a potential treatment option for patients with moderate-to-severe chronic plaque psoriasis Dermira raises $136 million through a follow-on equity financing Dermira announces positive topline results from the Phase 3 clinical program evaluating glycopyrronium tosylate (formerly DRM04) as a potential treatment option for patients with primary axillary hyperhidrosis Dermira announces topline results from the Phase 2b program evaluating olumacostat glasaretil in patients with acne vulgaris Dermira raises $104 million through a follow-on equity financing Dermira begins a Phase 3 program for glycopyrronium tosylate in patients with primary axillary hyperhidrosis Dermira begins a Phase 2b program for olumacostat glasaretil in patients with acne vulgaris Dermira begins a Phase 3 program for CIMZIA in patients with moderate-to-severe chronic plaque psoriasis Dermira goes public, raising $113 million, and is listed on NASDAQ as DERM Dermira raises $49 million in a Series C financing from existing investors and new healthcare-focused funds Dermira enters into a collaboration agreement with UCB S.A. to develop and commercialize CIMZIA as a treatment for patients with moderate-to-severe chronic plaque psoriasis Dermira raises $35 million in a Series B financing with investments from Osaka-based Maruho Co., Ltd., a leading dermatology company in Japan, and existing investors Bay City Capital, New Enterprise Associates and Canaan Partners Dermira initiates hyperhidrosis development program Dermira raises $34 million in a Series A financing with investments from Bay City Capital, New Enterprise Associates and Canaan Partners Dermira acquires olumacostat glasaretil, a topical product candidate as a potential treatment for acne vulgaris Gene is a co-founder of Dermira, our Chief Medical Officer and a member of our board of directors. Prior to founding Dermira, he served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma. He was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, he served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. He is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002. Company Our experienced board members work closely with the Dermira leadership team to foster a culture of accountability and responsibility. They support our efforts to identify, develop and commercialize truly novel therapies for patients and the healthcare professionals who serve them. Our board represents a diverse collection of academic, business and government expertise. Founder & Chief Medical Officer, Dermira Founder & Chief Medical Officer, Dermira Dr. Bauer is a co-founder of Dermira, our Chief Medical Officer and a member of our board of directors. Prior to founding Dermira, he served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma. He was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, he served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. He is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002. Dr. Cohen joined Dermira as a director in 2014 after previously serving as a scientific advisor since our inception. He has held a variety of positions at the New York University School of Medicine, including Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis, and Director of Occupational and Environmental Dermatology. He has served as a lecturer of Environmental Sciences at the Columbia University School of Public Health, and has been an attending physician at the Ronald O. Perelman Department of Dermatology at the Tisch Hospital at New York University Medical Center and at Bellevue Hospital Center. Dr. Craves has been a director of Dermira since 2010. He is an investment partner, a Managing Director and a co-founder of Bay City Capital (BCC), and has served as a member of the board of directors and Chairman of the executive committee of BCC since June 1997. Prior to founding BCC, he founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. Dr. Craves served as Executive Vice President of Schering Berlin, Inc. and Chief Executive Officer and President of Berlex Laboratories, Inc. He was also the founding Chairman of the board of directors and Chief Executive Officer of Codon Devices, Inc. and co-founder of Creative Biomolecules.